Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02254785
Title Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer
Recruitment Unknown status
Gender male
Phase Phase II
Variant Requirements No
Sponsors British Columbia Cancer Agency
Indications

prostate adenocarcinoma

Therapies

Abiraterone

Enzalutamide

Cabazitaxel

Age Groups: adult
Covered Countries CAN


No variant requirements are available.